

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Norio Hamada, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Corporate Officer, Joint General Manager, Corporate Planning Division and General Manager, Public and Investor Relations Office (TEL: 03-6838-2803)

“KYOSOMIRAI PHARMA CO., LTD.”, a New Business Line of TOHO HOLDINGS

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) is pleased to announce that Yell Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada; hereinafter “Yell Pharmaceutical”), the wholly-owned subsidiary, has changed its name to “KYOSOMIRAI PHARMA CO., LTD.” (hereinafter “KYOSOMIRAI PHARMA”) on November 1, 2016 and under the new structure in addition to contracted manufacture of prescription pharmaceuticals Yell Pharmaceutical has conducted as business, it will involve in development, manufacture and sales business of prescription pharmaceuticals centered on generic drugs.

1. Background and purpose of anew businessline

As a corporate group engaged in the medical, health and nursing care sector and under the corporate slogan, “Total commitment to good health”, TOHO HOLDINGS conducts businesses such as pharmaceutical wholesaling, management of pharmacies, development and provision of customer support systems, etc., and at the same time, actively promotes community healthcare collaboration and makes positive commitments to the home medical and nursing care sector.

TOHO HOLDINGS has now concluded that it is necessary to contribute to restructuring of supply chains which respond to the rapidly changing market environment including the promotion of using generic drugs the government has set as a target(increasing the market share of generic drugs to 80% as soon as possible from 2018 to 2020)and the expansion of specialty drugs and orphan drugs.

KYOSOMIRAI PHARMA will realize a pharmaceutical distribution based on its unique inspections on the quality in order to enhance the trustof citizens and medical professionals with regard to pharmaceuticals.

Looking into the near future and taking maximum advantage of TOHO HOLDINGS managerial resources, KYOSOMIRAI PHARMAwill strive for business development with the aim to establish an innovative business scheme of integrated manufacture and sales which accurately responds to customers’ demands and to stably and effectively provide high quality and high value added pharmaceuticals.

2. Outline of KYOSOMIRAI PHARMA

1.Head Office	1-4-4Hiromachi, Shinagawa-ku, Tokyo 140-0005, Japan
2.Marunouchi Office	GranTokyo South Tower 12F, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo 100-6613, Japan
3.Capital	199.23 million yen
4.Executives (as of November 1,2016)	Representative director and senior advisor: Norio Hamada Representative director and chairman: Ryuzo Takada Representative director and president: Atsushi Udoh Exective vice president: Yasuyuki Kumada Part-time director: Seiji Ohara Auditor: Takaho Hirano